$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other

Novo Initiates Icosema COMBINE 4 Ph3 Trial; Eccogene Initiates Ph1 Oral GLP-1RA Study; Ionis and Teladoc Q4 ’23 Earnings

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Eccogene, Ionis, and Teladoc. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home